Losing the opportunity to study influenza drugs.
Meyerhoff
Andrea
A
Division of Clinical Pharmacology, Johns Hopkins School of Medicine, Osler 501, 600 N Wolfe St, Baltimore, MD 21287, USA. ameyerh1@jhmi.edu
Lietman
Paul
P
D000146:Acids, Carbocyclic; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003517:Cyclopentanes / Q000627:therapeutic use*; D004196:Disease Outbreaks; D017277:Drug Approval; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; C414210:peramivir